Monthly Oncology Tumor Boards: A Multidisciplinary Approach to Individualized Patient Care - Bladder Cancer

September 24, 2020

Multidisciplinary Management of Bladder Cancer
With an increasing number of treatment options for both non–muscle invasive bladder cancer (NMIBC) and advanced urothelial bladder cancer available, it is important for physicians to understand these various treatments and identify which option is likely to bring the greatest benefit to a specific patient. While intravesical bacillus Calmette Guérin (BCG) is often a preferred treatment method for NMIBC, recent BCG shortages and the clinical challenge of BCG-unresponsive disease have led to the development of new treatment approaches in this setting. In addition, the treatment landscape for metastatic or locally advanced bladder cancer has become increasingly complex requiring education on treatment selection and sequencing.

Target Audience

This educational program is designed to meet the educational needs of physicians/oncologists, nurse practitioners, nurses, physician assistants, pharmacists, and other health care professionals who manage patients with cancer.

Learning Objectives

Following this activity, participants should be able to:

  • Integrate current and evolving approaches for treatment into the management of non–muscle invasive bladder cancer.
  • Compare and contrast the systemic therapy options for patients with locally advanced or metastatic bladder cancer with patient characteristics and biomarker testing to guide therapy choice.
  • Review the results of recent and emerging clinical trials for patients with non–muscle invasive or metastatic bladder cancer.
Additional information

This activity is supported by educational grants from:

  • AstraZeneca
  • Clovis Oncology, Inc.
  • Daiichi Sankyo, Inc.
  • GlaxoSmithKline
  • Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC
  • Lilly
  • Novartis
  • Puma Biotechnology
  • Seattle Genetics, Inc.
  • Taiho Oncology, Inc.

This activity is supported by independent educational grants from:

  • Astellas and Pfizer, Inc.
  • Merck  & Co., Inc.

This activity is supported by independent medical education grants from:

  • Bristol Myers Squibb
  • Sanofi Genzyme

This educational activity is supported by medical education grants from:

  • Exelixis, Inc.
  • Karyopharm Therapeutics
Course summary
Available credit: 
  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 CCM clock hours
  • 1.00 Participation
Course opens: 
Course expires: 
Event starts: 
09/24/2020 - 1:00pm EDT
Event ends: 
09/24/2020 - 2:00pm EDT

Michael R. Harrison, MD
Duke Cancer Institute

Brant A. Inman, MD, MSc
Duke Cancer Institute

Bridget F. Koontz, MD
Duke Cancer Institute


NCCN Medical Education Disclosure Policy
It is the policy of NCCN that every 12 months, all faculty, moderators, activity planners and all internal planning staff participating in NCCN continuing education activities are expected to disclose any financial relationships with a commercial interest as defined by the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support. In addition, all faculty presentations have been reviewed for adherence to the ACCME’s Standards for Commercial Support (the provider develops activities/educational interventions independent of commercial interests [SCS 1, 2 and 6] by experts on the topics). 

Per the ACCME Standards for Commercial Support, individuals who do not disclose relevant financial relationships will be disqualified from involvement in the CE activity as a content developer, planner, or presenter. A complete list of individuals’ relationships with external entities is available upon request.

NCCN continuing education considers financial relationships to create a “conflict of interest” when an individual has both a financial relationship with a commercial interest and the opportunity to affect CE content about the products or services of a commercial interest with which he/she and/or a spouse or partner has a financial relationship.

NCCN continuing education considers “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that create a conflict of interest. NCCN does not set a minimal dollar amount for relationships to be significant. Inherent in any amount is the incentive to maintain or increase the value of the relationship. 

Faculty Disclaimers  
All faculty for this continuing education activity are competent in the subject matter and qualified by experience, training, and/or preparation for the tasks and methods of delivery.

Faculty presentations may include discussion of off-label use. Faculty will disclose that the use in question is not currently approved by the FDA per the product labeling.

Faculty Disclosures
The faculty listed below discloses the following relevant financial relationships:
Brant A. Inman, MD, MSc
Anchiano Therapeutics: Grant/Research Support
Bristol-Myers Squibb Company: Grant/Research Support
Combat Medical: Grant/Research Support
Dendreon Corporation: Grant/Research Support
FerGene: Consulting Fee
FKD Therapies: Grant/Research Support
Genentech, Inc.: Grant/Research Support
Nucleix: Grant/Research Support
QED Therapeutics, Inc.: Grant/Research Support
TARIS Biomedical LLC: Grant/Research Support
UroGen Pharma, Inc.: Grant/Research Support

Bridget F. Koontz, MD
Janssen Pharmaceutica Products, LP: Grant/Research Support
Springer Publishing: Royalty Income

Michael R. Harrison, MD
Bayer HealthCare: Honoraria
Bristol-Myers Squibb Company: Grant/Research Support
Exelixis Inc.: Consulting Fee; Grant/Research Support: Product/Speakers Bureau
Fujifilm Corporation: Scientific Advisor
Genentech, Inc.: Consulting Fee
Janssen Pharmaceutica Products, LP: Consulting Fee
Merck & Co., Inc.: Grant/Research Support
Pfizer Inc.: Grant/Research Support

NCCN Staff Disclosures
The NCCN Activity Planning staff listed below discloses no relevant financial relationships:
Melissa Esplen; Mark A. Geisler; Kristina M. Gregory, RN, MSN, OCN; Kristin Kline Hasson; Rose Joyce; Karen Kanefield; Lisa Perfidio, MS; Shannon Ryan, CMP; Kathy Ann Smith, CHCP; Sarah Weinstein

The NCCN Clinical staff listed below discloses no relevant financial relationships:
Lisa Gurski, PhD

In support of improving patient care, National Comprehensive Cancer Network (NCCN) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

NCCN designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

NCCN designates this educational activity for a maximum of 1.0 contact hour.

NCCN designates this knowledge-based continuing education activity for 1.0 contact hour (0.10 CEUs) of continuing education credit. UAN: JA4008196-0000-20-073-L01-P

Physician Assistants 
NCCN has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credit. PAs should only claim credit commensurate with the extent of their participation.

Case Managers
This program has been pre-approved by The Commission for Case Manager Certification to provide continuing education credit to CCM® board certified case managers. The course is approved for 1.0 CE contact hour. Activity Code: I00043341; Approval #: 200138255

Available Credit

  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 CCM clock hours
  • 1.00 Participation


Please login or register to take this course.

This webinar was presented live one time only on Thursday, September 24, 2020, from 1:00 - 2:00 PM EDT (UTC -4).

Required Hardware/software

To complete this activity, users will need:

  • A device with an Internet connection and sound playback capability
    • One of the two latest versions of Google Chrome, Mozilla Firefox, or Safari
    • Internet Explorer is no longer supported
  • Adobe Reader or other PDF reader software for certificate viewing/printing